These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36176397)

  • 21. Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score-matching studies.
    Li M; Zhang B; Chen Q; Zhang L; Mo X; Chen Z; Jin Z; Chen L; You J; Zhang S
    Head Neck; 2021 Jun; 43(6):1912-1927. PubMed ID: 33644916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
    Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
    Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J
    Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
    Wang C; Tang X; Wang J; Song J; Xu Y
    Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
    Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
    Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of induction and adjuvant chemotherapy in combination with concurrent chemoradiotherapy for nasopharyngeal cancer: a Bayesian network meta-analysis of published randomized controlled trials.
    Yu H; Gu D; He X; Gao X; Bian X
    Onco Targets Ther; 2016; 9():159-70. PubMed ID: 26793000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
    Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma.
    Li T; Yang F; Ma K; Lv L
    Eur Arch Otorhinolaryngol; 2021 Sep; 278(9):3333-3344. PubMed ID: 33517538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis.
    Tang SQ; Xu C; Wang XS; Tang LL; Li WF; Chen L; Mao YP; Guo R; Liu Q; Sun Y; Ma J
    Oral Oncol; 2020 Jun; 105():104686. PubMed ID: 32283514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis.
    Bongiovanni A; Vagheggini A; Fausti V; Mercatali L; Calpona S; Di Menna G; Miserocchi G; Ibrahim T
    Crit Rev Oncol Hematol; 2021 Apr; 160():103244. PubMed ID: 33582249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
    Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
    Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Zhang J; Chen S; Li G; Zhang W; Qin T; Yin P; Huang H; Jiang H
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1087-1097. PubMed ID: 28429051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
    Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
    Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
    Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.
    Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ
    Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J; Thephamongkhol K
    BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis.
    Zhang L; Jiang N; Shi Y; Li S; Wang P; Zhao Y
    Sci Rep; 2015 Jun; 5():10798. PubMed ID: 26041604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
    Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
    BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stage-specific concurrent chemoradiotherapy with or without induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective, population-based study.
    Xia WX; Liang H; Lv X; Wang L; Ye YF; Ke LR; Xu LH; Guo X; Xiang YQ
    Cancer Manag Res; 2019; 11():9813-9827. PubMed ID: 31819619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.